Crossmark

The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases

Published Online: 2021-03-06

Published Print: 2021-04

Authors

Elliott, Jesse https://orcid.org/0000-0002-2501-1641
Wells, George A.

Coyle, Doug
License Information

Text and Data Mining valid from 2021-03-06

Version of Record valid from 2021-03-06
More Information

Article History

Accepted: 6 February 2021

First Online: 6 March 2021

Declarations

:

: No funding was received for the preparation of this letter.

: Jesse Elliott, George A. Wells, and Doug Coyle have no conflicts of interest that are directly relevant to the content of this letter.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors contributed equally to the writing of this Letter.

Document is current